title: HSV-TK/IL-2 gene therapy for glioblastoma multiforme.
abstract: We performed a clinical trial of gene therapy in patients with recurrent glioblastoma multiforme based on retroviral vector-mediated combined delivery of interleukin-2 and thymidine kinase of herpes simplex virus (HSV)-1. Treatment consisted of intratumor injection of retroviral vector-producing cells, followed by intravenous ganciclovir administration. The primary endpoints of the study were the evaluation of the safety of the treatment and demonstration of transduction of tumor cells. Here, we report details on the clinical protocol and the methods used.
authors: Department of Histology, Microbiology and Medical Biotechnologies, University of Padova, Italy.
authors: Luisa
authors: L
authors: Barzon
authors: Monia
authors: M
authors: Pacenti
authors: Elisa
authors: E
authors: Franchin
authors: Federico
authors: F
authors: Colombo
authors: Giorgio
authors: G
authors: Palù
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic / Q000009:adverse effects / Q000379:methods*; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D005909:Glioblastoma / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics* / Q000627:therapeutic use*; D008875:Middle Aged; D018579:Patient Selection; D012190:Retroviridae / Q000235:genetics; D018139:Simplexvirus / Q000201:enzymology*; D013937:Thymidine Kinase / Q000235:genetics* / Q000627:therapeutic use; D014161:Transduction, Genetic
chemical_list: D007376:Interleukin-2; D013937:Thymidine Kinase